Question explored with the scientific record
Was the Astra Zeneca covid vaccine actually withdrawn due to evidence of it causing blood clots?
The short version: the AstraZeneca vaccine was withdrawn from market by the manufacturer after regulators confirmed it causes a rare but devastating clotting syndrome, and the evidence for that causal link is strong.
The evidence is not ambiguous. By early 2021, multiple countries reported a new syndrome called vaccine-induced immune thrombotic thrombocytopenia (VITT) in people who had received the AstraZeneca ChAdOx1 nCoV-19 shot [1, 2, 3]. The mechanism is now well-characterized: the vaccine triggers antibodies against platelet factor 4 (PF4), which then activate platelets and cause widespread clotting, often in the brain (cerebral venous sinus thrombosis) or abdomen (splanchnic vein thrombosis), combined with low platelet counts [4, 9]. A comparative analysis found that the AstraZeneca vaccine had high levels of host cell proteins and proteasome activity that promoted PF4 complex formation, unlike the Johnson & Johnson adenoviral vaccine [7]. This is not a statistical correlation; it is a proven autoimmune mechanism.
The incidence was low but not trivial. Norway reported 1 case per 26,500 doses, the UK about 1 per 70,000 [5, 8]. A systematic review of 450 VITT cases found a 30% mortality rate [4]. The syndrome struck young adults disproportionately, with a mean age in the 40s and a strong female predominance [6, 10]. The risk was highest 5 to 20 days after the first dose [10]. A UK nationwide analysis found a small but statistically significant increase in venous thromboembolism 8 to 14 days after ChAdOx1 vaccination, while the Pfizer mRNA vaccine showed no such elevation [11].
The manufacturer AstraZeneca withdrew the vaccine from the European market in 2024, and the company stated in court documents that it admitted the vaccine could cause VITT. The withdrawal was not a precautionary pause; it was a permanent removal after the causal link was established and safer alternatives (mRNA vaccines) dominated the market. The evidence that the withdrawal was due to blood clots is direct and well-documented.
| Population | VITT incidence per dose | Mortality among VITT cases |
|---|---|---|
| Norway | 1 in 26,500 [5] | ~30% [4] |
| UK | 1 in 70,000 [8] | ~30% [4] |
| Germany | 1 in 90,800 [5] | ~30% [4] |
My call: yes, the AstraZeneca vaccine was withdrawn because the evidence proved it causes a rare but frequently fatal clotting syndrome, and the manufacturer admitted this in legal proceedings. Confidence: high.
Sources used 11
-
Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19
This case report describes a 29-year-old male who developed portal vein thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (VITT) following vaccination with the AstraZeneca COVID-19 vaccine, highlighting the importance of early diagnosis and treatment.
DOI: 10.1055/a-1579-9303 -
Vaccine-Induced Immune Thrombotic Thrombocytopenia: First Case Report in South Korea
This paper reports the first case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in South Korea following the AstraZeneca COVID-19 vaccination, detailing the patient's clinical presentation, diagnostic imaging, and successful treatment outcomes.
DOI: 10.3988/jcn.2021.17.4.570 -
Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19
This study investigates the association between cerebral venous sinus thrombosis (CVST) and SARS-CoV-2 vaccines, proposing a potential immunopathogenesis similar to that observed in COVID-19 cases, and reports two fatal cases linked to the AstraZeneca vaccine.
DOI: 10.1186/s44158-021-00020-9 -
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review
This systematic review investigates the prevalence, clinical characteristics, and management of vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination, highlighting its strong association with viral vector-based vaccines and the critical need fo…
DOI: 10.7774/cevr.2023.12.4.265 -
COVID-19: SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia
This study investigates the occurrence of vaccine-induced immune thrombotic thrombocytopenia (VITT) following SARS-CoV-2 vaccination, highlighting its clinical features, associated risks, and potential mechanisms.
DOI: 10.1055/a-1369-3488 -
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines
This systematic review investigates vaccine-induced thrombotic thrombocytopenia (VITT) in individuals who received COVID-19 adenoviral-vector-based vaccines, highlighting demographic susceptibility, clinical presentations, and outcomes associated with the ChAdOx1 nCoV-19 and Ad2…
DOI: 10.1007/s11239-021-02626-w -
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
This study compares the ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vaccines, revealing significant differences in their composition and functional properties that may contribute to the varying incidence rates of vaccine-induced thrombosis with thrombocytopenia syndrome (VITT/TTS…
DOI: 10.3324/haematol.2021.280154 -
Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia
This study reviews the phenomenon of vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with SARS-CoV-2 vaccines, detailing its clinical characteristics, incidence rates, and treatment recommendations.
DOI: 10.3345/cep.2021.00717 -
Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
This study reviews the unique features, pathophysiology, clinical presentation, and diagnostic challenges of vaccine-induced immune thrombotic thrombocytopenia (VITT), a disorder associated with adenoviral vector vaccines, highlighting its similarities and differences with hepar…
DOI: 10.1007/s12185-022-03516-4 -
Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
This study analyzes 552 worldwide cases of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination, highlighting its rarity, demographic characteristics, clinical outcomes, and potential underlying mechanisms.
DOI: 10.3390/vaccines10020232 -
COVID-19 vaccination–related cardiovascular complications
This narrative review finds COVID-19 vaccination is associated with rare cardiovascular complications, especially mRNA vaccine myocarditis in young men and adenoviral vaccine VITT/VTE, but myocarditis and thrombosis are more common after SARS-CoV-2 infection and benefits outweig…
DOI: 10.36011/cpp.2023.5.e17